Follow us on Twitter
twitter icon@FreshPatents


Pharmaceutically Acceptable Salt patents

      

This page is updated frequently with new Pharmaceutically Acceptable Salt-related patent applications.




 Heterocyclyl-pyridinyl-based biphosphonic acid, pharmaceutically acceptable salt thereof, composition thereof and  use thereof patent thumbnailHeterocyclyl-pyridinyl-based biphosphonic acid, pharmaceutically acceptable salt thereof, composition thereof and use thereof
The present invention relates to novel compounds, compositions containing same and methods for inhibiting human farnesyl pyrophosphate synthase or for the treatment or prevention of disease conditions using said compounds;. .
The Royal Institution For The Advancement Of Learning/mcgill University


 N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors patent thumbnailN1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
Or a pharmaceutically acceptable salt of the compound, wherein r1, r2, r3, z, a1, l and a2 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-coa carboxylase enzyme(s) in an animal.. .

 Mnk inhibitors and methods related thereto patent thumbnailMnk inhibitors and methods related thereto
Or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein r1, r2, r3, r4a, r4b, r5, r6, r7, r8, w1, w2, y and n are as defined herein. Also described are pharmaceutically acceptable compositions of formula i compounds as well as methods for utilizing the compounds of formula i and the pharmaceutically acceptable compositions of formula i compounds as inhibitors of mnk as well as therapeutics for the treatment of diseases such as cancer..

 Piperidin-1 -yl and azepin-1 -yl carboxylates as muscarinic m4 receptor agonists patent thumbnailPiperidin-1 -yl and azepin-1 -yl carboxylates as muscarinic m4 receptor agonists
The present invention provides muscarinic m4 receptor agonists of formula (i) and pharmaceutically acceptable salts thereof, wherein m, n, p, q, r, r2 and r3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases such as schizophrenia, alzheimer's disease and various cognitive disorders as well as in the treatment or alleviation of pain.. .
Takeda Pharmaceutical Company Limited


 Azole benzene derivative patent thumbnailAzole benzene derivative
The present invention provides: a compound represented by formula (i) or a pharmaceutically acceptable salt thereof, which has an excellent inhibitory activity on xanthine oxidase and is useful as a therapeutic agent or a prophylactic agent for diseases associated with xanthine oxidase, such as gout, hyperuricemia, tumor lysis syndrome, urinary tract stone, hypertension, dyslipidemia, diabetes, cardiovascular diseases including arteriosclerosis and heart failure, renal diseases including diabetic nephropathy, respiratory diseases including chronic obstructive pulmonary disease, inflammatory bowel disease or autoimmune diseases; and a medicine or a pharmaceutical composition comprising the compound or the salt as an active ingredient.. .
Teijin Pharma Limited


 Nsaids derivatives and uses thereof patent thumbnailNsaids derivatives and uses thereof
The present invention discloses novel compounds derived from nsaids and pharmaceutically acceptable salts thereof. Other aspects of the invention relate to use of the nsaid derivatives in treating inflammatory diseases and pharmaceutical compositions thereof..
Research Foundation Of The City University Of New York


 Stereochemically enriched compositions for delivery of nucleic acids patent thumbnailStereochemically enriched compositions for delivery of nucleic acids
A pharmaceutically acceptable salt thereof, a solvate thereof, or a solvate of a pharmaceutically acceptable salt thereof, the composition characterized in that greater than a first threshold amount of the total amount of chemical entities of formula i in the composition: are chemical entities of formula i.a, wherein the first threshold amount is 50%; or are chemical entities of formula i.b.1, wherein the first threshold amount is 25%; or are chemical entities of formula i.b.2, wherein the first threshold amount is 25%, wherein the chemical entities of formula i.a, i.b.1, and i.b.2, are described herein, and methods of using such compositions, for example, for the delivery of a polynucleotide in vivo.. .

 Neprilysin inhibitors patent thumbnailNeprilysin inhibitors
Where r1-r5 and x are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity.

 Method for the synthesising 4-piperidin-4-yl-benzene-1,3-diol and the salts of same and novel compound tert-butyl 4-(2,4-dihydroxy-phenyl)-4-hydroxy-piperidine-1-carboxylate patent thumbnailMethod for the synthesising 4-piperidin-4-yl-benzene-1,3-diol and the salts of same and novel compound tert-butyl 4-(2,4-dihydroxy-phenyl)-4-hydroxy-piperidine-1-carboxylate
And the pharmaceutically acceptable salts thereof. Also described, is tert-butyl 4-(2,4-dihydroxy-phenyl)-4-hydroxy-piperidine-1-carboxylate as a novel intermediate compound.

 Biguanide derivative, preparation method thereof, and pharmaceutical composition containing same as an active ingredient patent thumbnailBiguanide derivative, preparation method thereof, and pharmaceutical composition containing same as an active ingredient
A biguanide derivative compound with n4-n5 substitution, which is represented by formula 1, or a pharmaceutically acceptable salt thereof, a method of preparing the same, and a pharmaceutical composition containing the same as an active ingredient are provided. The biguanide derivative may exhibit excellent effect on activation of ampk and inhibition of cancer cell proliferation in a low dose, compared with conventional drugs, and thus, may be useful to treat diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer, etc..
Hanall Biopharma Co., Ltd.


Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids

Or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein r1a, r1b, r2a, r2b, r3a, r3b, r4a, r4b, r5, r6, r7, r8, r9, l1, l2, a, b, c, d and e are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided..

Design of short oligonucleotides as vaccine adjuvants and therapeutic agents

The invention provides a method of treating a microbial infection in a subject and a method of improving an immune system response in a subject against a disease, condition, infection, or virus thereof, by administering an effective amount of a nucleoside, short oligonucleotide compound or an analog thereof, or a pharmaceutically acceptable salt, racemate, enantiomer, diastereomer, geometric isomer, or tautomer thereof. In addition, the invention provides methods for treating or preventing a viral infection, bacterial infection, parasitic infection, or fungal infection in a subject (such as, a human).
Spring Bank Pharmaceuticals, Inc.

Method for administering omega-conopeptide

The present invention is directed to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl 1, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the ω-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound.
Jazz Pharmaceuticals International Limited

Prophylactic or therapeutic drug for constipation

New drugs useful in the prevention or treatment of constipation are provided, in which sglt1 inhibiting compounds, in particular, a 4-isopropylphenyl glucitol compound represented by the following formula (i), or pharmaceutically acceptable salts thereof are contained as an active ingredient:. .
Taisho Pharmaceutical Co., Ltd.

Substituted bisphenyl butanoic phosphonic acid derivatives as nep inhibitors

Or a pharmaceutically acceptable salt thereof, wherein r1, r2 and r3 are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses.

Methods and products for increasing the rate of healing of tissue wounds

Disclosed are methods for increasing the rate of healing of a tissue wound by administering a composition including a therapeutically effective amount of at least one cationic steroid antimicrobial (csa). Also disclosed herein are methods of promoting wound healing in a subject in need of such promotion, comprising administering a composition comprising a therapeutically effective amount of at least one csa.
Brigham Young University

Methods for treating fungal infections

Disclosed herein are methods of treating fungal infections in a patient, comprising identifying a patient in need of treatment and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (csa), or a pharmaceutically acceptable salt thereof. Kits comprising such compositions and instructions on such methods are also contemplated herein..
Brigham Young University

Methods of treating flushing associated with carcinoid tumors and carcinoid syndrome

A method of treating flushing associated with carcinoid tumors and carcinoid syndrome in a patient in need thereof comprising topically applying a pharmaceutical composition comprising an effective amount of an alpha adrenergic receptor agonist, pharmaceutically acceptable salt thereof, or combinations thereof; and a pharmaceutically acceptable carrier to the site of the flushing is claimed.. .
Galderma S.a.

Analogs of pridopidine, their preparation and use

This invention also provides an impurity or a salt thereof for use, as a reference standard to detect trace amounts of the impurity in a pharmaceutical composition comprising pridopidine or a pharmaceutically acceptable salt thereof. This invention further provides a process for producing a pridopidine drug product comprising obtaining a pridopidine drug substance and mixing the pridopidine drug substance with suitable excipients so as to produce the pridopidine drug product.

Transdermal patch

A patch containing a storage layer retaining a drug or a pharmaceutically acceptable salt thereof and an adhesive layer which are formed on a support, wherein the adhesive layer contains a thermoplastic elastomer, and a non-volatile hydrocarbon oil in more than 50 parts by weight and not more than 800 parts by weight per 100 parts by weight of the elastomer, and the adhesive layer optionally further contains a tackifier at a content of not more than 10 wt %.. .
Km Transderm Ltd.

Platinum compounds of malonic acid derivative having leaving group containing amino or alkylamino

Disclosed are a class of platinum compounds of malonic acid derivatives having a leaving group containing an amino or alkylamino, and pharmaceutically acceptable salt thereof, preparation method thereof and pharmaceutical composition containing the compounds. Also disclosed are uses of the compounds for treating cell proliferative diseases especially cancers.
Beijing Fswelcome Technology Development Co., Ltd

Pyridopyrimidine or pyrimidopyrimidine compound, prepration method, pharmaceutical composition, and use thereof

The present invention belongs to the field of pharmaceutical chemistry. In particular, the present invention relates to a pyridopyrimidine or pyrimidopyrimidine compound as represented by general formula (i), or an isomer thereof or a pharmaceutically acceptable salt, ester, prodrug or solvate thereof, a preparation method, a pharmaceutical composition and uses thereof in preparing a mtor inhibitor.
Fudan University

Imidazo pyridine compounds

The present invention provides compounds of the formula i, wherein x is a bond or ch2; q is ch2 or o; l is selected from the group consisting of —och2— and —ch2o—; or a pharmaceutically acceptable salt thereof. Compounds of the invention are autotaxin inhibitors..
Eli Lilly And Company

Macrocyclic compounds as hcv entry inhibitors

Compounds of formula i, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis c virus (hcv) and may be useful in treating those infected with hcv..
Bristol-myers Squibb Company

Chemical compounds 542

To pharmaceutically acceptable salts thereof, to methods of using them to treat bacterial infections, and to methods for their preparation.. .

Macrocyclic molecules as hcv entry inhibitors

Compounds of formula i, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis c virus (hcv) and may be useful in treating those infected with hcv..
Bristol-myers Squibb Company

2,6,7 substituted purines as hdm2 inhibitors

The present invention provides 2,6,7 substituted purines as described herein or a pharmaceutically acceptable salt thereof. The representative compounds are useful as inhibitors of the hdm2 protein.
Merck Sharp & Dohme Corp.

Novel tetrahydropyridopyrimidinone derivative

An object is to provide a novel compound having a higher mgat2 inhibitory activity than conventional compounds. A compound represented by the following general formula (i) or a pharmaceutically acceptable salt thereof is provided..
Ajinomoto Co., Inc.

Dihydropyrido pyrimidine compounds as autotaxin inhibitors

The present invention provides compounds of the formula (i) or a pharmaceutically acceptable salt thereof. Compounds of the invention are autotaxin inhibitors useful in the treatment of pain associated with osteoarthritis..
Eli Lilly And Company

Substituted imidazo[1,2-a]pyridine compounds as tropomyosin receptor kinase a (trka) inhibitors

Pharmaceutically acceptable salts, pharmaceutically acceptable solvates or stereoisomers thereof, their use as tropomyosin receptor kinase (trk) family protein kinase inhibitors, method of making and pharmaceutical compositions comprising such compounds.. .

Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors

The present invention provides compounds of formula (i) or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein w, x, n, s, t, and ra are as described herein. The present invention relates generally to selective inhibitors of histone deacetylase and to methods of making and using them..
The Board Institute, Inc.

2-aminopyrazine derivatives as csf-1 r kinase inhibitors

The present invention provides a compound of formula (i) or a pharmaceutically acceptable salt, n-oxide, hydrate or solvate thereof: wherein: ring a, r1, r2, n, x, v, w, z, ring b, [linker] and r areas defined herein. The compounds are useful as inhibitors of csf-1r kinase.
Chroma Therapeutics Ltd.

4-pyrimidinylamino-benzenesulfonamide derivatives and their use for the inhibition of polo-like kinase 1 (plk1) for the treatment of cancer and their use for the treatment of bacterial infections

The present invention relates to 4-pyrimidinylamino-benzenesulfonamide derivatives of general formula (i) and pharmaceutically acceptable salts, solvates, hydrates, regioisomeric and polymorphic forms thereof, processes for manufacturing of them, the use of them, as well as pharmaceutical compositions containing at least one of them as pharmaceutically active agent(s) together with pharmaceutically acceptable carrier, excipient and/or diluents, especially for the inhibition of polo-like kinases (plks) and the treatment of cancer. Said 4-pyrimidinylamino-benzenesulfonamide compounds have been also identified as new drug candidates for the prevention and/or treatment of infectious diseases like bacterial diseases e.g.
Vichem Chemie Kutató Kft

N1-cyclic amine-n5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same

The present invention provides an n1-cyclic amine-n5-substituted biguanide derivative compound represented by formula 1, a method of preparing the same and a pharmaceutical composition including the biguanide derivative or the pharmaceutically acceptable salt thereof as an active ingredient. The biguanide derivatives have an effect of inhibiting cancer cell proliferation, cancer metastasis and cancer recurrence by activation of ampk, even when administered in a small dose compared with conventional drugs..
Hanall Biopharma Co., Ltd.

Stable aqueous solution

The present invention provides an aqueous liquid preparation having high stability to light and heat, which contains (3-{2-[4-isopropyl-2-(4-trifluoromethyl)phenyl-5-thiazolyl]ethyl}-5-methyl-1,2-benzisoxazol-6-yl)oxyacetic acid or a pharmaceutically acceptable salt thereof, and tyloxapol or octoxynol.. .
Senju Pharmaceutical Co., Ltd.

Treatment of neurological disorders

A treatment of a neurological disorder, including hypoxia, oxygen-glucose deprivation and acute brain trauma in a subject involves administering an effective amount of selenate or a pharmaceutically acceptable salt thereof to the subject. The treatment prevents incurring a symptom, holds in check a symptom or treats an existing symptom of the neurological disorder..
Velacor Therapeutics Pty Ltd.

Administration of nedd8-activating enzyme inhibitor and hypomethylating agent

The present disclosure relates to methods for the treatment of cancer in patients in recognized need of such treatment. The methods comprise administering to such a patient an nae inhibitor or a pharmaceutically acceptable salt thereof, such as ((1s,2s,4r)-4-(4-((1s)-2,3-dihydro-1h-inden-1-ylamino)-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate (mln4924) or {(1s,2s,4r)-4-[(6-{[(1r,2s)-5-chloro-2-methoxy-2,3-dihydro-1h-inden-1-yl]amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl)methyl sulfamate (i-216), and a hypomethylating agent or a pharmaceutically acceptable salt thereof, such as azacitidine or decitabine.
Millennium Pharmaceuticals, Inc.

Compositions and methods for cancer therapy

The invention provides compositions and methods to treat cancer with an agent that selectively promotes cancer cell death relative to non-malignant cells by mechanisms that include increased oxidative stress (“a therapeutic agent”) or a pharmaceutically acceptable salt thereof, an inhibitor of hydroperoxide metabolism and a pharmaceutically acceptable diluent or carrier.. .
University Of Iowa Research Foundation

Compositions and methods for treating bone diseases and broken bones

Disclosed herein are methods of promoting osteogenesis in a subject, comprising administering a composition comprising a therapeutically effective amount of at least one cationic steroid antimicrobial (csa). Also disclosed herein are methods of promoting osteogenesis in a subject in need of such promotion, comprising administering a composition comprising a therapeutically effective amount of at least one csa.
Brigham Young University

Compounds and methods for modulating fxr

A stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of farnesiod x receptors (fxr).. .

Derivatives of pyrazole-substituted amino-heteroaryl compounds

And pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an inhibitor of anaplastic lymphoma kinase (alk)..

Combination of geranylgeranylacetone and ibudilast and methods of using same

The present invention relates generally to methods for treating progressive neurodegenerative diseases, including their progressive forms. In particular, the present invention pertains to methods of treating or preventing progressive neurodegenerative diseases and its associated symptoms by administration of a combination of geranylgeranylacetone (teprenone) and ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine), or pharmaceutically acceptable salts thereof..
Medicinova, Inc.

Multiparticulate pharmaceutical composition comprising a multitude of two kinds of pellets

Multiparticulate pharmaceutical composition comprising a multitude of two kinds of pellets, a and b, each comprising metoprolol or a pharmaceutically acceptable salt thereof as an active pharmaceutical ingredient, wherein the pellets a are coated with a coating layer comprising at least 30% by weight of a polymeric compound consisting of one or more (meth)acrylate copolymers polymerized from 20 to 40% by weight of ethyl acrylate, 60 to 80% by weight of methyl methacrylate and 0 or less than 5% by weight of methacrylic acid or acrylic acid, in an amount sufficient to result in an active pharmaceutical ingredient release profile according to usp in ph 6.8 test medium with a release rate of less than 20% after 4 hours, wherein the pellets b are not coated or coated with a coating layer and show an active pharmaceutical ingredient release profile according to usp in ph 6.8 test medium with an active pharmaceutical ingredient release rate of more than 40% after 4 hours, wherein the metoprolol release rate of the pellets a in ph 1.2 test medium according to usp with the addition of 40% (v/v) ethanol is •not more than 15% after 15 minutes •more than 15 up to 40% after 30 minutes, wherein the metoprolol release rate of the pellets b in ph 1.2 test medium according to usp with the addition of 40% (v/v) ethanol is •more than 15% after 15 minutes •more than 40% after 30 minutes and wherein the pellets a and b are present in the multiparticulate pharmaceutical composition in a relation resulting in a combined active pharmaceutical ingredient release profile of the multiparticulate pharmaceutical composition according to usp in ph 6.8 test medium with releases rates of •not more than 25% after 1 hour •20 to 40% after 4 hours •40 to 60% after 8 hours •not less than 80% after 20 hours.. .
Evonik Roehm Gmbh

Oral pharmaceutical composition comprising dabigatran etexilate

The present invention relates to an oral pharmaceutical composition comprising dabigatran etexilate or a pharmaceutically acceptable salt thereof, methods for preparing it and dosage forms for oral administration comprising said composition. The pharmaceutical composition is particularly useful as a medicament, especially as anticoagulant..
Hexal Ag

Macrocyclic inhibitors of flaviviridae viruses

And pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis c infections..

Neuroactive enantiomeric 15-, 16- and 17-substituted steroids as modulators for gaba type-a receptors

The present disclosure is generally directed to neuroactive enantiomeric 15-, 16- and 17-substituted steroids with additional optional substituents at carbons 3, 4, 6, 7, 10 and 13, and pharmaceutically acceptable salts thereof, for use as, for example, modulators for gaba type-a receptors. The present disclosure is further directed to pharmaceutical compositions comprising such compounds..
Washington University

Phosphatidylinositol 3-kinase inhibitors

Or pharmaceutically acceptable salts, isomers, or a mixture thereof, wherein n, m, q, a′, w1, w2, w3, r1, r2, and r3 are described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (pi3k) and are useful for treating conditions mediated by one or more pi3k isoforms.

Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors

And pharmaceutically acceptable salts thereof, which are inhibitors of pi3k, and compositions and methods of treatment related thereto.. .

Oxazolidone compound, preparing method and application thereof

The present invention relates to the field of a pharmaceutical compound, and more specifically, relates to a new oxazolidone compound, an enantiomer, a diastereoisomer and a raceme thereof, and a mixture thereof, and a pharmaceutically acceptable salt thereof, a preparation method thereof, an application thereof as a bioactive substance in a drug. The compound in the present invention has strong anticoagulant activity, does not affect the activity of thrombin, and can reduce the risk of hemorrhage.
Zhe Jiang Jutai Pharmaceutical Co., Ltd

Novel histone deacetylase inhibitors and their use in therapy

A compound of the formula: (i) or a pharmaceutically acceptable salt thereof, wherein: l is a 5-membered nitrogen-containing heteroaryl which is optionally fused to a benzene; y is a 5, 6 or 7-membered nitrogen-containing heteroaryl, which is optionally fused to a benzene; and w is a zinc-binding group. The compounds are hdac inhibitors and therefore have potential utility in therapy..
Karus Therapeutics Ltd

Phosphatidylinositol 3-kinase inhibitors

Or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein n, m, r1, r2, r3, r4, and r5 are described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (pi3k) and are useful for treating conditions mediated by one or more pi3k isoforms.

Phosphatidylinositol 3-kinase inhibitors

Or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein x, y, z, n, m′, a′, r1, r2, and r3 are described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (pi3k) and are useful for treating conditions mediated by one or more pi3k isoforms.

Phosphatidylinositol 3-kinase inhibitors

Or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein n, w, a′, b′, r1, r2, and r3 are described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (pi3k) and are useful for treating conditions mediated by one or more pi3k isoforms.

Substituted dihydroisoquinolinone compounds

In which r1, r2, r3, r4, l, x and z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.. .

Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof

Provided are processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoin-dolin-2-yl)piperidine-2,6-dione, or a pharmaceutically acceptable salt thereof.. .
Celgene Corporation

Phosphatidylinositol 3-kinase inhibitors

Or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein w, b, n, m, a′, r1, r2, and r3 are described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (pi3k) and are useful for treating conditions mediated by one or more pi3k isoforms.

Deuterated momelotinib

The present invention in one embodiment provides a compound of formula i, or a pharmaceutically acceptable salt thereof, wherein the variables shown in formula i are as defined in the specification.. .
Concert Pharmaceuticals Inc.

Prmt5 inhibitors and uses thereof

Described herein are compounds of formula (a), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting prmt5 activity.
Epizyme, Inc.

Pyrrole derivatives as alpha 7 nachr modulators

Disclosed is a compound of formula (i), wherein r1, r2, r3, r4, r5, r6, r7 and m are as described herein, as a modulator of nicotinic acetylcholine receptors particularly α7 subtype, its tautomeric forms, its stereoisomers, its pharmaceutically acceptable salts, its pharmaceutical composition, and its combinations with suitable medicaments. Also disclosed are a process of preparation of the compounds and the intended uses thereof in therapy, particularly in the prophylaxis and therapy of disorders such as alzheimer's disease, mild cognitive impairment, senile dementia, and the like..
Lupin Limited



Pharmaceutically Acceptable Salt topics:
  • Pharmaceutically Acceptable Salt
  • Pharmaceutically Acceptable Salts
  • Dimethyl Fumarate
  • Amelioration
  • Benzimidazole
  • Antiviral Agents
  • Hepatitis C Virus
  • Antiviral Agent
  • Antivirals
  • Hepatitis C
  • Diabetic Complications
  • Complication
  • Kidney Disease
  • Pyridoxamine
  • Neurodegenerative Disease


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Pharmaceutically Acceptable Salt for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Pharmaceutically Acceptable Salt with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.3321

    file did exist - 5665

    2 - 1 - 83